ELIQUIS® (apixaban) dosing | patients with renal or hepatic impairment | ELIQUIS UK
The use of direct oral anticoagulants in chronic kidney disease - Parker - 2018 - British Journal of Haematology - Wiley Online Library
No INRs! RNs Role Caring for Patients on Oral Anticoagulant Therapy - ppt download
Peripheral Matters | Dose-Reduced Direct Oral Anticoagulants: Practical Considerations - American College of Cardiology
Target-Specific Oral Anticoagulants
NOAC Dose-Adjustment Recommendations in Renal Impairment and AF | Download Table
Anticoagulation therapy in Atrial Fibrillation patients at high bleeding risk - It's Over 9000!
ELIQUIS® (apixaban) dosing | patients with renal or hepatic impairment | ELIQUIS UK
Warfarin Dabigatran Rivaroxaban Apixaban Edoxaban Target - ppt video online download
Safety and effectiveness of reduced-dose apixaban in Japanese patients with nonvalvular atrial fibrillation in clinical practice: A sub-analysis of the STANDARD study - ScienceDirect
Renal Outcomes in Anticoagulated Patients With Atrial Fibrillation - ScienceDirect
Antithrombotic Therapy in Patients With Chronic Kidney Disease | Circulation
Non–Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction - ScienceDirect
ELIQUIS® (apixaban) dosing | patients with renal or hepatic impairment | ELIQUIS UK
ELIQUIS® (apixaban) dosing | patients with renal or hepatic impairment | ELIQUIS IRELAND
Update on the Safety and Efficacy of Oral Anticoagulation in CKD and ESRD
Table 1 from Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical
Can I use DOAC in a patient with renal disease? - The Hospitalist
Anticoagulation in Concomitant Chronic Kidney Disease and Atrial Fibrillation: JACC Review Topic of the Week - ScienceDirect
Health Canada dosing algorithm for apixaban according to renal... | Download Scientific Diagram
Expert Opinion on the Use of Novel Oral Anticoagulants for Stroke Prevention in Non- valvular Atrial Fibrillation for the Primar
Anticoagulant risks may outweigh benefits for those on dialysis with atrial fibrillation
Direct Xa Inhibitor Levels | Test Fact Sheet
